DLL3 is also overexpressed in other poorly differentiated neuroendocrine cancers including SCLC and small cell bladder cancer (68, 69) and not expressed in benign tissues, and there are current clinical trials of DLL3-targeted T-cell engager therapies for patients with NEPC, SCLC, and other DLL3-expressing neuroendocrine carcinomas (NCT04429087, NCT04702737, NCT04471727). Here, DLL3 is linked to neuroendocrine carcinoma.